Sulbactam

A beta-lactamase inhibitor with very weak antibacterial action. The compound prevents antibiotic destruction of beta-lactam antibiotics by inhibiting beta-lactamases, thus extending their spectrum activity. Combinations of sulbactam with beta-lactam antibiotics have been used successfully for the therapy of infections caused by organisms resistant to the antibiotic alone.

Also Known As:

Networked: 704 relevant articles (129 outcomes, 128 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Lai, Chih-Cheng: 5 articles (04/2022 - 02/2020)
2.	Kohno, Shigeru: 5 articles (03/2015 - 01/2006)
3.	Tang, Hung-Jen: 4 articles (04/2022 - 09/2009)
4.	Zhang, Min: 4 articles (11/2021 - 01/2015)
5.	Lee, Wen-Sen: 4 articles (01/2019 - 12/2014)
6.	Bantar, C: 4 articles (06/2009 - 06/2000)
7.	Soutric, J: 4 articles (12/2002 - 06/2000)
8.	Wang, Minggui: 3 articles (05/2022 - 07/2013)
9.	Liu, Hong: 3 articles (01/2022 - 11/2017)
10.	Li, Wen-Bin: 3 articles (11/2021 - 01/2015)

Related Diseases

1.	Infections 07/01/2022 - "Hence, the increased sulbactam dose significantly improved efficacy in MDRAB lung infection (p = 0.049). " 05/01/2017 - "We did a comprehensive meta-analysis to explore the efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection. " 05/01/2017 - "Efficacy of sulbactam for the treatment of Acinetobacter baumannii complex infection: A systematic review and meta-analysis." 04/01/2001 - "These results show the efficacy of sulbactam in infections caused by susceptible strains of A. " 03/01/1990 - "Efficacy of sulbactam in an in vitro model of mixed aerobic/anaerobic infections."
2.	Pneumonia (Pneumonitis) 02/02/2023 - "A PK/PD evaluation for pneumonia should be performed in the lung tissue (the target site) rather than in the blood because sulbactam concentrations are lower in lung tissue. " 07/01/2019 - "Ampicilin-sulbactam was prescribed in 28.1% of pneumonia case in neonates in 2018. " 05/01/2017 - "pneumonia extended-spectrum β-lactamases(ESBL) was 84.6%(33/39) and 70.8%(17/24), the resistance rate to imipeniem was 12.8% and 25.0%, to cefperazone-sulbactam was 28.2% and 29.2%. " 06/01/2015 - "Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex." 11/01/2018 - "Probiotic Lactobacillus casei Shirota improves efficacy of amoxicillin-sulbactam against childhood fast breathing pneumonia in a randomized placebo-controlled double blind clinical study."
3.	Respiratory Tract Infections (Respiratory Tract Infection) 10/01/1991 - "Clinical efficacy: in subjects with lower respiratory tract infections, sulbactam/ampicillin cured 32 patients (72.72%) and ameliorated the clinical status of 8 patients (18.18%); efficacy rate: 90.9%).(ABSTRACT TRUNCATED AT 250 WORDS)" 08/01/2001 - "This study suggests that amoxicillin/sulbactam (500mg/500mg) is still a suitable option for treating community-acquired lower respiratory tract infections, allowing a b.i.d. " 07/01/1995 - "We performed clinical studies on sulbactam/cefoperazone (SBT/CPZ) for the treatment of geriatric patients with respiratory tract infections. " 02/01/2022 - "Aim To identify the common pathogens causing lower respiratory tract infections (LRTI), their antimicrobial susceptibility pattern, and determine the minimum inhibitory concentration (MIC) of sulbactam and colistin for Acinetobacter spp. " 08/01/2001 - "In order to establish a rationale for treating community-acquired lower respiratory tract infections, we assess here the pharmacodynamics of amoxicillin/sulbactam, 500mg/500mg, a formulation marketed in Argentina since 1988 and currently available in 17 countries, against the major pathogens, in comparison with that of a novel formulation (875mg/125mg, see J Chemother 2000; 12: 223-227). "
4.	Bacterial Infections (Bacterial Infection) 04/30/2022 - "Therefore, cefoperazone-sulbactam at a dose of 2 g/2 g twice daily is an effective and safe regimen for acute bacterial infection in patients with CKD." 07/01/2017 - "Safety and efficacy of a novel drug elores (ceftriaxone+sulbactam+disodium edetate) in the management of multi-drug resistant bacterial infections in tertiary care centers: a post-marketing surveillance study." 04/30/2022 - "A total of 155 patients with CKD received cefoperazone-sulbactam either at a dose of 2 g/2 g twice daily (study group) or adjusted according to renal function (control group) for the treatment of acute bacterial infection. " 06/01/1996 - "These studies have established the key role of sulbactam/ampicillin in the treatment of a wide variety of bacterial infections." 01/01/2008 - "Cefoperazone and sulbactam are prescribed in combination and used in the treatment of moderate to severe bacterial infections. "
5.	Fever (Fevers) 12/01/2022 - "However, 10 days later, she was re-hospitalized due to fever, and treated with cefoperazone sodium and sulbactam sodium. " 06/16/2021 - "After 8 h in the hospital, she had a high fever of 40 ℃, blood was drawn for culture, and 3 g of cefoperazone/sulbactam was administered. " 01/01/1989 - "Fever due to postoperative pulmonary complications occurred in one patient in the sulbactam/ampicillin group. " 07/01/2006 - "Fever and pulmonary infiltrates did not improve by using empiric antibacterial therapy (Cefoperazona-Sulbactam, Trimethoprim-Sulphametoxazol). " 01/01/1991 - "In the patients treated with sulbactam/ampicillin, a rapid decrease in the fever with the concomitant reduction in cough and sputum production was observed, with cure in 18 cases and improvement in six. "

Related Drugs and Biologics

1.	Ampicillin (Omnipen)
2.	Cefoperazone (Cefoperazone Sodium)
3.	beta-Lactamases (beta-Lactamase)
4.	Colistin (Coly-Mycin)
5.	Carbapenems (Carbapenem Antibiotics)
6.	Anti-Bacterial Agents (Antibiotics)
7.	beta-Lactamase Inhibitors
8.	Rifampin (Rifampicin)
9.	Tigecycline (Tygacil)
10.	Piperacillin

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Anesthesia
4.	Intravenous Administration
5.	Intravenous Injections